New Drug Approvals

Home » 2013 » May

Monthly Archives: May 2013

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Paypal donate

Blog Stats

  • 1,489,129 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,896 other followers

Follow New Drug Approvals on WordPress.com

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,896 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 29 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 29 year tenure till date Aug 2016, Around 30 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 25 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 13 lakh plus views on New Drug Approvals Blog in 212 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

Verified Services

View Full Profile →

Categories

Flag Counter

Top 10 experimental cancer drugs – 2013


Top 10 experimental cancer drugs – 2013

http://www.fiercebiotech.com/special-reports/top-10-experimental-cancer-drugs-2013?utm_medium=nl&utm_source=internal

Advertisements

FDA Accepts sNDA for Higher Concentration Dose of Copaxone


Teva Announces FDA Acceptance of sNDA for a Higher Concentration Dose of COPAXONE® Given Three Times a Week

http://www.pharmalive.com/fda-accepts-snda-for-higher-concentration-dose-of-copaxone

Glatiramer acetate (also known as Copolymer 1Cop-1, or Copaxone – as marketed by Teva Pharmaceuticals) is an immunomodulator drug currently used to treat multiple sclerosis. It is a random polymer of four amino acids found in myelin basic protein, namelyglutamic acid, lysine, alanine, and tyrosine, and may work as a decoy for the immune system. Glatiramer acetate is approved by the Food and Drug Administration (FDA) for reducing the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability.

Although the clinical definition of multiple sclerosis requires two or more episodes of symptoms and signs, glatiramer acetate is approved for treatment after single episodes. It is also used to treat relapsing-remitting multiple sclerosis. It is administered bysubcutaneous injection.

Ireland passes reference pricing, pro-generics law


Ireland passes reference pricing, pro-generics law

 

http://www.pharmatimes.com/Article/13-05-29/Ireland_passes_reference_pricing_pro-generics_law.aspx

GENERICS WEB- RALOXIFENE (DRUG IN FOCUS)


GENERICS WEB- RALOXIFENE (DRUG IN FOCUS).

Inspection Management – How to Pass EU and FDA Inspections


Inspection Management – How to Pass EU and FDA Inspections

http://www.gmp-compliance.org/ecanl_616_0_seminar_7737_n.html?goback=%2Egmr_4751810%2Egde_4751810_member_245242986

Canada: GMP Requirements now Applicable to all APIs


http://www.gmp-compliance.org/ecanl_616_0_news_3702_7819,S-WKS_n.html?goback=%2Egmr_4751810%2Egde_4751810_member_245243312

Gaseous Sterilization – New USP General Chapter


Gaseous Sterilization – New USP General Chapter <1229.7>

http://www.gmp-compliance.org/ecanl_616_0_news_3697_7918_n.html?goback=%2Egmr_4751810%2Egde_4751810_member_245243237

Procurement meets GMP – GMP Requirements for Purchase and Procurement


http://www.gmp-compliance.org/ecanl_616_0_seminar_7887_n.html?goback=%2Egmr_4751810%2Egde_4751810_member_245243624

Amgen And Astellas Announce Japan Alliance


seagull

 read all at

http://www.pharmalive.com/amgen-and-astellas-announce-japan-alliance

Glaxo Acquires Vaccine Developer for $325M


seagull

 

http://www.pharmalive.com/glaxo-acquires-vaccine-developer-for-325m

%d bloggers like this: